Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938771 | 0.99 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5605782 | 0.99 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL6375235 | 0.97 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5604980 | 0.97 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL13730902 | 0.89 | PTGS2 (0.93) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL3043548 | 0.89 | PTGS2 (0.69) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL12103290 | 0.87 | PTGS2 (0.82) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL13109325 | 0.85 | PTGS2 (0.64) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL13109318 | 0.83 | PTGS2 (0.65) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5494432 | 0.82 | PTGS2 (0.74) | PTGS2PTGS1MAPTCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771461-A2 | NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-04-11 | — | — | EP | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| WO-2006003013-A2 | NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | WO | claimed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| US-8691869-B2 | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs | NICOX S.A. (FR) | 2014-04-08 | — | — | US | disclosed |
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | NICOX SA (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1771461-A2 | NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| WO-2006003013-A2 | NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | FASN, PTGS1, NOS2 | PTGS2 5/4885PTGS1 2/4885MAPT 3918/4885 |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS2 653/4885PTGS1 515/4885MAPT 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.